{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'been reviewed by the Investigator and is true and accurate. The Investigator will be required', 'to electronically sign off the eCRF.', 'The data will be verified for missing data, inconsistencies, and for necessary medical', 'clarifications. Queries arising from these checks will be flagged to the trial site, and the trial', 'site staff will correct data, confirm or clarify data as appropriate. The CRO will provide the', 'details of the review process in a data management plan and monitoring plan. Any change,', 'including the issuing of queries, will be fully audit trailed by the EDC application, meaning', 'the name of the person, time, and date stamp are captured, as well as the reason for change.', 'Data will also be provided by third party vendors, such as the results generated by the central', 'labs, IRT provider, or centralized ECG reading. This data will need to be reconciled with the', 'data recorded in the eCRF before it can be merged with the eCRF data into the clinical', 'database. The CRO will provide a data management plan detailing this reconciliation.', 'Adverse events, concomitant diseases/medical history terms will be assigned to a lowest', 'level term (LLT) and a preferred term (PT) and will be classified by high level term (HLT),', 'high level group term, and primary system organ class (SOC) according to the Medical', 'Dictionary for Regulatory Activities (MedDRA) thesaurus.', 'Prior and concomitant medications will be classified according to active drug substance using', 'the World Health Organization Drug Dictionary (WHO-DD). The generic name, the', 'preferred name, and the WHO name will be assigned using WHO-DD thesaurus.', 'The Anatomical Therapeutic Chemical (ATC) classes will be assigned to the prior and', 'concomitant medications.', '9.5.', 'Quality Assurance Audit', 'Trial sites, the trial database and trial documentation may be subject to Quality Assurance', \"audit during the course of the trial by the Sponsor or Sponsor's designee (CRO or other\", 'vendor) on behalf of Sponsor. In addition, inspections may be conducted by regulatory', 'bodies at their discretion.', '10.', 'ETHICS', '10.1.', 'Institutional Review Board or Independent Ethics Committee', 'The Investigator will provide the Sponsor or designee with documentation of IRB/IEC', 'approval of the protocol and informed consent documents before the trial may begin at the', 'trial sites. The Investigator will supply documentation to the Sponsor or designee of the', \"required IRB/IEC's annual renewal of the protocol, and any approvals of revisions to the\", 'informed consent document or amendments to the protocol.', 'argenx BVBA', 'Confidential', 'Page 94 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'The Investigator will report promptly to the IRB/IEC, any new information that may', 'adversely affect the safety of patients or the conduct of the trial. Similarly, the Investigator', 'will submit written summaries of the trial status to the IRB/IEC annually, or more frequently', 'if requested by the IRB/IEC. Upon completion of the trial, the Investigator will provide the', 'IRB/IEC with a brief report of the outcome of the trial, if required.', '10.2.', 'Ethical Conduct of the Trial', 'This trial will be conducted and the informed consent will be obtained according to the', 'ethical principles stated in the Declaration of Helsinki (2008), the applicable guidelines for', 'GCP, or the applicable drug and data protection laws and regulations of the countries where', 'the trial will be conducted.', '10.3.', 'Patient Information and Informed Consent', 'The ICF will be used to explain the risks and benefits of trial participation to the patient in', 'simple terms before the patient is screened. A separate ICF will be given in case of', 'pregnancy of a female partner of male patient. The ICF contains a statement that the consent', 'is freely given, that the patient is aware of the risks and benefits of entering the trial, and that', 'the patient is free to withdraw from the trial at any time. Written consent must be given by', 'the patient and/or legally acceptable representative, after the receipt of detailed information', 'on the trial.', 'All ICFs must be available in the local and vernacular languages required at the site and', 'include patient information sheets/brochures that outline the trial procedures. All ICF(s) must', 'be signed and dated by the patient or a legally acceptable representative.', 'For patients who are unable to read and write, the patient information sheet and ICF(s)', 'should be read to the patient in his/her native language in the presence of a legally acceptable', 'representative who is literate and not affiliated with the trial. The patient having understood', 'the information given to him/her in the presence of a legally acceptable representative will', 'thumbprint the ICF(s) and the same will be countersigned by the legally acceptable', 'representative. If the patient or legally acceptable representative cannot read, then an', 'impartial witness will witness and attest the entire consent process and will be required to', 'sign the ICF.', \"Confirmation of a patient's informed consent must also be documented in the patient's\", 'medical record prior to any testing under this protocol, including Screening tests and', 'assessments.', 'The Investigator is responsible for ensuring that informed consent is obtained from each', 'patient or legally acceptable representative and for obtaining the appropriate signatures and', 'dates on the informed consent document prior to the performance of any protocol procedures', 'argenx BVBA', 'Confidential', 'Page 95 of 110']\n\n###\n\n", "completion": "END"}